Quisovalimab is under clinical development by Avalo Therapeutics and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Quisovalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Quisovalimab overview
AVTX-002 (AEVI-002, KHK-252067,SAR-252067) is under development for the treatment of severe pediatric onset Crohn’s disease, moderate to severe Crohn's disease, COVID-19 cytokine storm induced acute respiratory distress syndrome, pneumonia, acute lung injury and non-eosinophilic asthma (NEA). It is administered through subcutaneous route. It is a fully human anti-light monoclonal antibody. LIGHT is a tumor necrosis factor (TNF) super-family member that is implicated as a key mediator of inflammation.
It was under development for the treatment of ulcerative colitis.
Avalo Therapeutics overview
Avalo Therapeutics, formerly Cerecor is a biopharmaceutical company that develops and commercializes novel products in the fields of neurology and pediatrics. The company’s products include prescription medications, prescription devices and dietary supplements. Its pipeline products offer treatment in the areas of neurogenic orthostatic hypotension, parkinsons disease, seizures in epilepsy and deoxyguanosine kinase deficiency. Avalo Therapeutics‘ prescription medications comprise aciphex sprinkle, cefaclor, millipore tablets and dose packs and millipred oral solution, among others. The company also offers dietary supplements such as chewable tablets and drops. Avalo Therapeutics is headquartered in Baltimore, Maryland, the US.
For a complete picture of Quisovalimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
